| 产品描述： | Valiglurax (VU0652957) is a potent, orally active and selective mGlu4 positive allosteric modulator with EC50 values of 64.6 nM and 197 nM for hmGlu4/Gqi5 and rmGlu4 GIRK, respectively. Valiglurax is a central nervous system (CNS) penetrant. Valiglurax can be used in research of Parkinson's disease |
| 靶点： |
mGluR;GluR |
| 体内研究： |
Valiglurax (VU0652957; 0.3-30 mg/kg; po) 以剂量依赖性方式逆转 haloperidol (HY-14538) 诱导的大鼠僵直症 (HIC)。 Animal Model: haloperidol-induced catalepsy (HIC) in rats Dosage: 0.3-30 mg/kg Administration: Oral administration Result: Reversed haloperidol (HY-14538)-induced catalepsy (HIC) in rats in a dose-dependent manner. |
| 参考文献： |
1. Panarese JD, et, al. Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease. ACS Med Chem Lett. 2018 Oct 16;10(3):255-260. |
| 溶解性： |
Soluble in DMSO |
| 保存条件： |
-80℃（运输条件：冰袋低温运输） |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
3.037 ml |
15.184 ml |
30.369 ml |
| 5 mM |
0.607 ml |
3.037 ml |
6.074 ml |
| 10 mM |
0.304 ml |
1.518 ml |
3.037 ml |
| 50 mM |
0.061 ml |
0.304 ml |
0.607 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京